Repository logo
 
Publication

Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae

2021-01-01Journal article Open access
Simple item page
dc.contributor.authorHadad, Ronza
dc.contributor.authorCole, Michelle Jayne
dc.contributor.authorEbeyan, Samantha
dc.contributor.authorJacobsson, Susanne
dc.contributor.authorTan, Lit Yeen
dc.contributor.authorGolparian, Daniel
dc.contributor.authorErskine, Simon
dc.contributor.authorDay, Michaela
dc.contributor.authorWhiley, David
dc.contributor.authorUnemo, Magnus
dc.contributor.authorEuropean collaborative group
dc.date.accessioned2022-01-31T16:45:56Z
dc.date.available2022-01-31T16:45:56Z
dc.date.issued2021-01-01
dc.descriptionEuropean collaborative group: Raquel Abad Torreblanca, Lena Rós Ásmundsdóttir, Eszter Balla, Irith De Baetselier, Beatrice Bercot, Thea Bergheim, Maria José Borrego, Susanne Buder, Robert Cassar, Michelle Cole, Alje van Dam, Claudia Eder, Steen Hoffmann, Blazenka Hunjak, Samo Jeverica, Vesa Kirjavainen, Panayiota Maikanti-Charalambous, Vivi Miriagou, Beata Młynarczyk-Bonikowska, Gatis Pakarna, Peter Pavlik, Monique Perrin, Joseph Pett, Paola Stefanelli, Kate Templeton, Magnus Unemo, Jelena Viktorova, Hana Zákouckápt_PT
dc.descriptionPortugal: Maria-José Borrego (INSA)pt_PT
dc.description.abstractBackground: Accurate molecular assays for prediction of antimicrobial resistance (AMR)/susceptibility in Neisseria gonorrhoeae (Ng) can offer individualized treatment of gonorrhoea and enhanced AMR surveillance. Objectives: We evaluated the new ResistancePlus® GC assay and the GC 23S 2611 (beta) assay (SpeeDx), for prediction of resistance/susceptibility to ciprofloxacin and azithromycin, respectively. Methods: Nine hundred and sixty-seven whole-genome-sequenced Ng isolates from 20 European countries, 143 Ng-positive (37 with paired Ng isolates) and 167 Ng-negative clinical Aptima Combo 2 (AC2) samples, and 143 non-gonococcal Neisseria isolates and closely related species were examined with both SpeeDx assays. Results: The sensitivity and specificity of the ResistancePlus® GC assay to detect Ng in AC2 samples were 98.6% and 100%, respectively. ResistancePlus® GC showed 100% sensitivity and specificity for GyrA S91 WT/S91F detection and 99.8% sensitivity and specificity in predicting phenotypic ciprofloxacin resistance. The sensitivity and specificity of the GC 23S 2611 (beta) assay for Ng detection in AC2 samples were 95.8% and 100%, respectively. GC 23S 2611 (beta) showed 100% sensitivity and 99.9% specificity for 23S rRNA C2611 WT/C2611T detection and 64.3% sensitivity and 99.9% specificity for predicting phenotypic azithromycin resistance. Cross-reactions with non-gonococcal Neisseria species were observed with both assays, but the analysis software solved most cross-reactions. Conclusions: The new SpeeDx ResistancePlus® GC assay performed well in the detection of Ng and AMR determinants, especially in urogenital samples. The GC 23S 2611 (beta) assay performed relatively well, but its sensitivity, especially for predicting phenotypic azithromycin resistance, was suboptimal and further optimizations are required, including detection of additional macrolide resistance determinant(s).pt_PT
dc.description.sponsorshipThis work was supported by the O¨rebro County Council Research Committee and the Foundation for Medical Research at O¨rebro University Hospital, O¨rebro, Sweden.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Antimicrob Chemother. 2021 Jan 1;76(1):84-90. doi: 10.1093/jac/dkaa381.pt_PT
dc.identifier.doi10.1093/jac/dkaa381pt_PT
dc.identifier.issn0305-7453
dc.identifier.urihttp://hdl.handle.net/10400.18/7897
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Press/ British Society for Antimicrobial Chemotherapypt_PT
dc.relation.publisherversionhttps://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkaa381pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectPhenotypept_PT
dc.subjectAzithromycinpt_PT
dc.subjectCiprofloxacinpt_PT
dc.subjectGonococcal Infectionpt_PT
dc.subjectCross Reactionspt_PT
dc.subjectDrug Resistance, Microbialpt_PT
dc.subjectGenomept_PT
dc.subjectNeisseriapt_PT
dc.subjectNeisseria Gonorrhoeaept_PT
dc.subjectRNA, Ribosomal, 23spt_PT
dc.subjectSoftwarept_PT
dc.subjectGenitourinary Systempt_PT
dc.subjectMacrolidespt_PT
dc.subjectSurveillance, Medicalpt_PT
dc.subjectInfecções Sexualmente Transmissíveispt_PT
dc.titleEvaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeaept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage90pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage84pt_PT
oaire.citation.titleJournal of Antimicrobial Chemotherapypt_PT
oaire.citation.volume76pt_PT
rcaap.embargofctAcesso de acordo com página web do editor da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
dkaa381.pdf
Size:
302.28 KB
Format:
Adobe Portable Document Format
Download

Collections

DDI - Artigos em revistas internacionais